Literature DB >> 27096295

[Access to medicines prescribed for acute health conditions in adults in South and Northeast Brazil].

Vera Maria Vieira Paniz1, Isabel Carolina Coelho Flores Cechin1, Anaclaudia Gastal Fassa2, Roberto Xavier Piccini3, Elaine Tomasi2, Elaine Thumé4, Denise Silva da Silveira2, Luiz Augusto Facchini2.   

Abstract

This was a cross-sectional study within Brazil's Project for the Expansion and Consolidation of Family Health, 2005, with the objective of universal and free access to the medication prescribed in the last medical appointment for acute health problems and to estimate the degree to which access may have improved with inclusion of the medicines in prevailing policies and programs. The sample included 4,060 adults living in the area of primary health care units in 41 municipalities in South and Northeast Brazil. Access was greater in the South (83.2%) than in the Northeast (71%), and free access was similar (37%), with a greater share by the Family Health Program (FHP) when compared to the traditional model, especially in the Northeast. Some 60% of prescribed medicines and 50% of those on the National List of Essential Medicines (RENAME) were paid for. No variation was observed in the proportion of medicines present on the prevailing RENAME list and access. However, 40% of the medicines that were paid for can currently be obtained through the Popular Pharmacy Program. The latter program appears to emerge as a new way to guarantee access to medicines prescribed in the health system.

Mesh:

Substances:

Year:  2016        PMID: 27096295     DOI: 10.1590/0102-311X00009915

Source DB:  PubMed          Journal:  Cad Saude Publica        ISSN: 0102-311X            Impact factor:   1.632


  3 in total

1.  Did the Family Health Strategy have an impact on indicators of hospitalizations for stroke and heart failure? Longitudinal study in Brazil: 1998-2013.

Authors:  Denise de Fátima Barros Cavalcante; Valéria Silva Cândido Brizon; Livia Fernandes Probst; Marcelo de Castro Meneghim; Antonio Carlos Pereira; Gláucia Maria Bovi Ambrosano
Journal:  PLoS One       Date:  2018-06-26       Impact factor: 3.240

2.  Impacts of a Brazilian pharmaceutical program on the health of chronic patients.

Authors:  Aléssio Tony Cavalcanti de Almeida; Edvaldo Batista de Sá; Fabiola Sulpino Vieira; Rodrigo Pucci de Sá E Benevides
Journal:  Rev Saude Publica       Date:  2019-01-31       Impact factor: 2.106

3.  Performance of a pharmaceutical services regionalization strategy policy in Minas Gerais, Brazil: Pre-post analysis from ERAF project.

Authors:  Tatiana Chama Borges Luz; Ana Karine Sarvel de Castro; Isabela Cristina Marques; Betania Barros Cota; Jèssica de Castro Alves; Michael Robert Law
Journal:  Front Pharmacol       Date:  2022-09-02       Impact factor: 5.988

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.